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Abstract
Background
Patients with advanced chronic kidney disease (CKD) experience complex functional and
structural changes of the cardiopulmonary and musculoskeletal system. This results in
reduced exercise tolerance, quality of life and ultimately premature death. We investigated
the relationship between subjective measures of health related quality of life and objective,
standardised functional measures for cardiovascular and pulmonary health.
Methods
Between April 2010 and January 2013, 143 CKD stage-5 or CKD5d patients (age 46.0
±1.1y, 62.2% male), were recruited prospectively. A control group of 83 healthy individuals
treated for essential hypertension (HTN; age 53.2±0.9y, 48.22% male) were recruited at
random. All patients completed the SF-36 health survey questionnaire, echocardiography,
vascular tonometry and cardiopulmonary exercise testing.
Results
Patients with CKD had significantly lower SF-36 scores than the HTN group; for physical
component score (PCS; 45.0 vs 53.9, p<0.001) and mental component score (MCS; 46.9
vs. 54.9, p<0.001). CKD subjects had significantly poorer exercise tolerance and cardiore-
spiratory performance compared with HTN (maximal oxygen uptake; VO2peak 19.9 vs
25.0ml/kg/min, p<0.001). VO2peak was a significant independent predictor of PCS in both
groups (CKD: b = 0.35, p = 0.02 vs HTN: b = 0.27, p = 0.001). No associations were noted
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between PCS scores and echocardiographic characteristics, vascular elasticity and cardiac
biomarkers in either group. No associations were noted between MCS and any variable.
The interaction effect of study group with VO2peak on PCS was not significant (ΔB =
0.08; 95%CI -0.28–0.45, p = 0.7). However, overall for a given VO2peak, the measured
PCS was much lower for patients with CKD than for HTN cohort, a likely consequence of
systemic uremia effects.
Conclusion
In CKD and HTN, objective physical performance has a significant effect on quality of life;
particularly self-reported physical health and functioning. Therefore, these quality of life
measures are indeed a good reflection of physical health correlating highly with objective
physical performance measures.
Introduction
The sense of well-being and ability to function productively in daily life is poor in patients
with advanced chronic kidney disease (CKD) compared to the general population [1–4]. For
patients with CKD, impaired quality of life is a consistent predictor of more objective patient
outcomes [5–10].
Health related quality of life (HRQoL) assessment of patients is becoming an increasingly
important clinical tool. One of the most widely used generic HRQoL instruments in CKD is
the Medical Outcomes Study 36-Item Instrument Short Form Health Survey (SF-36)[5, 8–11].
The SF-36 assesses eight generic scales of HRQoL. Two composite measures, the physical com-
ponent summary (PCS) and the mental component summary (MCS), are derived from the
eight scales [12].
Patients with advanced CKD are at high risk of cardiovascular disease (CVD). Complex
changes in both the cardiac and vascular systems results in structural and functional changes that
can lead to reduced exercise tolerance, quality of life and ultimately premature death [13–16].
Exercise capacity relies on the health of the circulatory system. The association between the
somewhat subjective measures of a self-reported HRQoL and more objective measures such as
cardiac structural and functional measures are not well understood. A reduction in exercise
capacity limits the range of physical activities that a patient can accomplish. The importance of
this is underscored by a previously reported association between mortality and physical activ-
ity assessed through questionnaires in CKD patients[3, 4, 8, 9]. A similar association was also
observed for generic and CKD specific HRQoL instruments with poorer HRQoL resulting in
an increased probability of hospitalisation and mortality [8–10]. Particularly the physical sum-
mary score was previously shown to have a strong association with a higher risk of death and
may therefore be a subjective, but reliable measure for cardiac dysfunction and cardiac death
[8]. Impaired quality of life has not only been recognized as a marker of hypertrophic cardio-
myopathy [17] and chronic heart failure [18], but has also been described as cause for develop-
ing cardiovascular disorders[19, 20].
In this prospective clinical cohort study we hypothesize that objective functional measures
for uremic cardiomyopathy and vasculopathy are associated with subjective measures of qual-
ity of life. Patients with essential hypertension and maintained kidney function served as con-
trol group.
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Methods
Study design
Patients aged over 18 years with CKD stage-5 or CKD5d who were either kidney transplant
recipients enrolled prior to surgery or transplant waitlisted were included at a tertiary aca-
demic clinical centre (University Hospital Coventry and Warwickshire NHS Trust, UK). In
parallel a control group was recruited at random from the community through primary care
database, comprising healthy individuals being treated for essential hypertension (HTN), with-
out evidence of CKD, diabetes, CVD (heart failure, ischemic heart disease, cerebrovascular dis-
ease) or secondary causes for hypertension. In both groups, patients with pre-existing chronic
lung disease, inability to cycle due to physical limitation, age over 75 and BMI>38kg/m2 were
excluded.
Complete study protocol included the SF-36 Health Survey questionnaire, cardiopulmo-
nary exercise testing and clinical assessment (including office brachial blood pressure, echo-
cardiography, vascular tonometry and blood sampling) prior to exercise testing. For patients
on hemodialysis, these assessments were carried out on the first non-dialysis day that was at
least 12 hours after the last dialysis session in order to avoid the effects of hemodialysis-
induced myocardial stunning and minimize the impact of volume load variability on the indi-
ces of cardiovascular structure and function [21]. This study was approved by the Black Coun-
try Research Ethics Committee (REC:09/H1202/113) and adhered to the declaration of
Helsinki. Written informed consent was obtained from all participants.
Between April 2010 and January 2013, we had screened 184 patients with advanced CKD
with 143 patients recruited (5 unable to exercise due to physical limitations, 14 did not provide
consent and 22 did not complete questionnaire protocol. In the control group, 94 subjects
with HTN were screened with 83 recruited (following the exclusion of 5 who had physical
comorbid conditions precluding exercise testing, 2 who did not provide consent and 4 did not
complete questionnaire protocol). The analysis of HRQoL data presented in this paper was
part of a larger study investigating CKD subgroups. (In the larger study the analysis distin-
guished between pre-kidney transplant, transplant waitlisted CKD patients, and the control
group. Recruitment to the three study groups was intended to be 1:1:1, respectively.) However,
for the analysis of HRQoL we were only interested in exploring differences between CKD
(combined pre-kidney transplant and transplant waitlisted, n = 143) and HTN (n = 83)
patients.
SF-36 short form health survey (version 2)
The SF-36 is the most widely used health related quality of life score worldwide. It is a single
item that indicates perceived changes in a person’s health [12]. There are 36 outcomes that can
be split into 8 domains: physical function, role physical, bodily pain, general health, vitality,
social functioning, emotional role and mental health. Two summary components scores, phys-
ical component summarising the first four domains and mental component summarising the
latter four domains are also calculated. Domain and summary scores are transformed into a
scale 0–100. Higher scores equate to a better health related quality of life. A licence was
acquired from QualityMetric Health Outcome Solution, USA (Licence number: QM027853)
and calculation software (QualityMetric health outcome™ scoring software 4.5) used.
Cardiopulmonary exercise testing
An experienced blinded investigator performed exercise testing. Cardiopulmonary exercise
testing (CPET) was conducted using an electronically braked, upright cycle ergometer to
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maximal tolerance at an individual work rate. Continuous breath-by-breath analysis (VIASYS,
MasterScreen CPX1 Hoechberg, Germany) was performed. Equipment was calibrated using
standard reference gases and a 3-litre syringe. Each patient rested for 3 minutes followed by 3
minutes of unloaded pedalling prior to workload increments and continuous 12-lead ECG was
recorded. All patients continue until symptom limited volitional fatigue. VO2peak was mea-
sured as the greatest VO2 achieved during the final 20-second averaging of peak exercise. Pre-
dicted VO2peak was determined by the Wasserman and Hansen equation [22]. The V-slope
method was used with analyses of ventilatory equivalents and end-tidal gas tension plots in
order to calculate VO2AT.
Echocardiography
2-dimensional, Doppler and tissue Doppler transthoracic echocardiography was performed
using Vivid 7, GE Healthcare, Horten, Norway ultrasound system according to a standardized
study protocol. Calculations included LV ejection fraction according to quantitative biplane
Simpson’s method, LV mass and LA volume. Mass and volume measures were indexed to
body surface area. Tissue Doppler imaging of the mitral annulus, sequentially at the lateral and
septal annular sites were obtained from the apical 4-chamber view. The ratio of early transmi-
tral flow velocity to averaged annular (septal and lateral) mitral velocity (E/mean e’) was taken
as an estimate of LV filling pressure. All measurements were undertaken according to the
American Society of Echocardiography [23] and analysed offline (EchoPac, GE Healthcare).
Measures of arterial compliance
Pulse wave analysis was performed on the radial artery and carotid-femoral arteries. Pulse
wave velocity (PWV) was determined by sequential recording of ECG-gated carotid and femo-
ral waveforms using the high fidelity micromanometer (SPC-301, Miller Instrument, Houston,
Texas). An augmentation index adjusted to a heart rate of 75 beats/minute (AIx75) was
recorded [24]. Measurements were derived using a validated radial-to-aortic transfer function
(SphygmoCor, AtCor Medical Pty Ltd, Australia). All measurements were made in triplicate
and mean values used for analysis.
Statistical methods
Variables are presented as mean, median or frequencies depending on distribution and vari-
able type. Differences in mean values for normally distributed variables were assessed using
independent samples t-tests. The Mann Whitney U test was used to assess variables that were
not normally distributed. PCS and MCS scores from SF-36 were the outcome variables of
interest in this study and thus used as dependant variable in regression modelling analysis.
Variables with p-value<0.1 were included in multiple regression analysis. Parameter estimates,
standard deviation and 95% confidence intervals were calculated for all regression predictors.
An interaction effect estimate is denoted ΔB and can be interpreted as the difference of the
slopes of the predictor between groups. All hypothesis tests were two-sided and a p-value of
<0.05 was used to indicate statistical significance. SPSS Software Version 22 was used to ana-
lyse data.
Results
Clinical characteristics
Baseline characteristics of both groups are described in Table 1.
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CKD subjects had a lower BMI (25.8 vs. 27.5kg/m2, p = 0.001), were younger (46.0 vs.
53.2years, p<0.001), received more B-blockers (38.0 vs 13.8%, p<0.001) for the treatment of
hypertension than HTN cohort. In contrast more HTN patients received ACEi/ARB (68.6 vs.
41.0%,<0.01) and diuretics (42.5 vs. 16.3%, p<0.001) than CKD patients. Hemoglobin (11.7
vs. 14.2g/dl, p<0.001) and albumin (43.4 vs. 46.7g/l, p<0.001) were lower but phosphate (1.6
vs. 1.2mmol/l, p<0.001), iPTH (36.7 vs. 3.6pmol/l, p<0.001), hs-CRP (7.3 vs. 2.4mg/l,
p<0.001), NT-pro-BNP (576.9 vs. 8.3pmol/L, p<0.001) and Troponin-T (36.1 vs. 5.1μg/L,
P<0.001) were higher in the CKD patients compared to the HTN group.
SF-36 short form health survey score. Full breakdown of physical and mental compo-
nent scores are described in Table 2.
The CKD cohort scored significantly lower than HTN patients for PCS (45.0 vs 53.9,
p<0.001) and MCS (46.9 vs. 54.9, p<0.001). Patients with CKD reported lower physical
Table 1. Characteristics of study populations.
CKD HTN p-value
Total number 143 83
Male sex, n (%) 89 (62.2) 40 (48.2) 0.08
BMI, kg/m2 25.8 ± 4.7 27.5 ± 3.4 0.001
Age, years 46.0 ± 1.1 53.2 ± 0.9 <0.001
Diabetes, n (%) 16 (11.2) 0 -
Hypertension, n (%) 133 (93.0) 83 (100.0) 0.03
Antihypertensives
ACEi/ARB, n (%) 68 (41.0) 51 (58.6) <0.01
Calcium antagonist, n (%) 87 (52.4) 39 (44.8) 0.3
B-blockers, n (%) 63 (38.0) 12 (13.8) <0.001
Diuretics, n (%) 27 (16.3) 37 (42.5) <0.001
CV disease (%) 16 (11.2) 0 -
Smoking, n (%) 73 (51.1) 44 (53) 0.5
Dialysis status, n (%)
Predialysis 35 (24.5) - -
Hemodialysis 91 (63.6) - -
Peritoneal dialysis 17 (11.9) - -
Biochemistry
Hemoglobin, g/dl 11.7 ± 1.5 14.2 ± 1.2 <0.001
Urea, mmol/l 18.2 ± 5.9 5.3 ± 1.2 <0.001
Creatinine, μmol/l 655.2 ± 2.0 72.7 ± 14.8 <0.001
eGFR, ml/min/1.73m2 9.2 ± 4.5 92.5 ± 15.0 <0.001
Albumin, g/l 43.4 ± 3.8 46.7 ± 2.3 <0.001
Calcium, mmol/l 2.2 ± 0.2 2.2 ± 0.1 0.8
Phosphate, mmol/l 1.6 ± 0.4 1.2 ± 0.3 <0.001
iPTH, pmol/l 36.7 ± 39.5 3.6 ± 1.3 <0.001
hs-CRP, mg/l 7.3 ± 15.8 2.4 ± 2.3 <0.001
NT-pro-BNP, pmol/L 576.9 ± 1345.9 8.3 ± 7.3 <0.001
Troponin-T, μg/L 36.1 ± 33.3 5.1 ± 2.4 <0.001
CKD = chronic kidney disease stage 5 or 5d; HTN = only hypertensive; BMI, body mass index; CV, cardiovascular; eGFR = estimated glomerular filtration
rate; iPTH = intact parathyroid hormone; hs-CRP = high sensitive C-reactive protein, NT-pro-BNP = N-terminal prohormone of brain natriuretic peptide.
Data are mean values with standard deviation (SD) or total count in sample with percentage (%). P-value by independent-samples t-test (continuous
variables) or χ2 (categorical variables).
https://doi.org/10.1371/journal.pone.0183926.t001
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function (74.6 vs. 94.4, p<0.001), physical role functioning (62.4 vs. 91.7, p<0.001), increased
bodily pain (70.2 vs. 81.0, p = 0.002) and reduced general health (45.0 vs. 70.2, p<0.001) com-
pared to the HTN cohort. A similar pattern was observed for individual domains of the mental
score. Graphical representations of these values are shown in Fig 1.
Measures of cardiovascular function. Cardiopulmonary exercise, echocardiographic and
applanation tonometric findings of the two groups are summarized in Table 3.
The CKD group had significantly poorer exercise tolerance and cardiorespiratory perfor-
mance compared with HTN for maximal oxygen uptake (VO2peak: 19.9 vs 25.0ml/kg/min,
p<0.001), anaerobic threshold (VO2AT: 11.7 vs. 14.8ml/kg/min, p<0.001), maximal work
load (109.8 vs 155.8Watt, p<0.001) and maximal heart rate (125.5 vs. 155.0bpm, p<0.001; 78.1
vs 93.0% of predicted, p<0.001).
LV mass index was significantly higher in the CKD than the HTN group (110.4 vs. 87.8g/
m2, p<0.001). Criteria for LV hypertrophy were present more frequently in CKD patients
than the HTN subjects (53.1 vs. 18.1%, p<0.001). The latter group had a higher LV ejection
fraction (66.1 vs. 60.7%, p<0.01) than the CKD patients. The measures of vascular compliance
were not significantly different in both groups. However, mean arterial pressure (MAP) was
lower in the CKD compared to the HTN group (98.8 vs. 104.0mmHg, p<0.001)
Independent predictors of the physical component score from the SF-36 health sur-
vey. Univariate linear regression analyses for the two groups are presented in Table 4.
In the CKD group a positive association was noted between VO2peak (b = 0.35, p = 0.02),
maximum work load (b = 0.04, p = 0.03), serum albumin (b = 0.40, p = 0.04) and PCS. There
was also positive correlation between the PCS and VO2peak (b = 0.27, p = 0.001), VO2AT
(b = 0.47, p = 0.002), heart rate at maximal exercise (b = 0.07, p = 0.03), maximum work load
(b = 0.03, p = 0.01) and MAP (b = 0.13, p = 0.04) in the HTN group. No associations were
noted between PCS and echocardiographic measures, vascular elasticity, hemoglobin, bio-
chemical markers of mineral metabolism, inflammation or cardiac markers in either group.
The MCS did not show any relationship with the tested variables in the CKD or HTN
group (data not shown).
Table 5 presents multiple regression models adjusted for demographic variables age, sex
and BMI, and additionally dialysis vintage in the CKD group.
Table 2. SF 36 score breakdown in the study cohorts.
CKD HTN p-value
Physical Component Score 45.0 ± 9.3 53.9 ± 5.5 <0.001
Physical Function 74.6 ± 21.2 94.4 ± 8.7 <0.001
Role Physical 62.4 ± 31.2 91.7 ± 17.0 <0.001
Bodily Pain 70.2 ± 27.0 81.0 ± 23.0 0.002
General Health 45.0 ± 20.8 70.2 ± 13.7 <0.001
Mental Component Score 46.9 ± 11.1 54.9 ± 7.6 <0.001
Vitality 44.7 ± 22.6 71.4 ± 17.1 <0.001
Social Functioning 66.8 ± 30.0 92.9 ± 16.5 <0.001
Role Emotional 79.4 ± 26.2 95.0 ± 16.1 <0.001
Mental Health 71.6 ± 20.2 83.1 ± 14.3 <0.001
Data are mean values with standard deviation (SD). Physical component score is a composite score for the subdomains physical function, role physical,
bodily pain and general health. Mental component score is a composite score for the subdomains vitality, social functioning, role emotional and mental
health.
https://doi.org/10.1371/journal.pone.0183926.t002
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Fig 1. A. Physical Component Summary Score and breakdown by domain in CKD and HTN cohorts. B. Mental
Component Summary Score and breakdown by domain in CKD and HTN cohorts.
https://doi.org/10.1371/journal.pone.0183926.g001
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The unstandardized regression coefficient represents the change in PCS while holding the
other variables constant. In the CKD group only VO2peak (b = 0.39, p = 0.03) was significantly
associated with PCS. For the HTN group a similar positive measured effect was observed
(VO2peak; b = 0.24, p = 0.02). Increasing age showed a decline in measured physical perfor-
mance (PCS) (b = -0.18, p = 0.02).
The effect of uremia on the physical component score from the SF-36 health survey.
There is no significant difference in the change of PCS with VO2peak between the 2 groups
(ΔB = 0.08; p = 0.7). However, lower PCS for a given VO2peak value in the CKD group com-
pared to the HTN group (Fig 2) suggest that the effect of uremia on cardiopulmonary function
characterised through a reduced VO2peak is perceived in a quantifiable reduction of physical
ability.
Discussion
The interaction between HRQoL measures and pathophysiological processes are complex.
Our prospective cohort study showed a clear positive relationship between objective integrated
Table 3. Measures of cardiovascular function in the study cohorts.
CKD HTN p-value
CPET
VO2peak, ml/kg/min 19.9 ± 5.4 25.0 ± 7.2 <0.001
VO2peak, % of predicted 68.4 ± 16.5 95.5 ± 20.7 <0.001
VO2AT, ml/kg/min 11.7 ± 2.3 14.8 ± 3.9 <0.001
VO2AT, % of predicted VO2peak 40.6 ± 9.2 56.9 ± 12.2 <0.001
RER at VO2peak 1.26 ± 0.1 1.22 ± 0.08 0.01
RER at AT 0.89 ± 0.01 0.94 ± 0.07 <0.001
Maximal work load, Watt 109.8 ± 42.4 155.8 ± 61.9 <0.001
Maximal heart rate, bpm 135.5 ± 25.0 155.0 ± 18.7 <0.001
Maximal heart rate, % of predicted 78.1 ± 13.9 93.0 ± 9.9 <0.001
Echocardiography
LV ejection fraction, % 60.7 ± 9.0 66.1 ± 6.0 <0.001
LV mass index, g/m2 110.4 ± 36.2 87.8 ± 17.0 <0.001
Left atrial volume index, ml/m2 27.7 ± 14.3 25.1 ± 7.6 0.08
E/mean e’ 8.9 ± 3.6 8.2 ± 1.8 0.07
LV geometry, n (%) <0.001
Normal geometry 31 ± 22.4 27 ± 32.5
Concentric remodelling 59 ± 41.2 41 ± 49.4
Concentric hypertrophy 55 ± 38.4 7 ± 8.4
Eccentric hypertrophy 21 ± 14.7 8 ± 9.6
Arterial measures
Alx75, % 23.1 ± 13.5 26.2 ± 12.1 0.07
PWV, m/s 8.6 ± 2.6 9.0 ± 2.0 0.1
Systolic blood pressure, mm Hg 136.1 ± 20.7 141.2 ± 13.4 0.03
Diastolic blood pressure, mm Hg 80.1 ± 12.0 85.3 ± 9.8 <0.001
Mean arterial pressure, mm Hg 98.8 ± 13.4 104.0 ± 1.0 <0.001
Data are mean values with standard deviation (SD). VO2peak, oxygen consumption at maximal exercise / kg body weight; VO2AT, oxygen uptake at the
point of anaerobic threshold / kg body weight; RER, respiratory exchange ratio; LV, left ventricle; Alx75, augmentation index corrected for heart rate of 75
beats/min; PWV, pulse wave velocity; E/mean e’, the ratio of peak early transmitral ventricular filling velocity to the averaged septal and lateral annular mitral
velocity.
https://doi.org/10.1371/journal.pone.0183926.t003
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functioning for the pulmonary, cardiac, circulatory and muscle metabolic system measured
with CPET and self-reported measures of HRQoL in all study patients. We demonstrated that
VO2peak is a strong predictor of PCS for both CKD and HTN cohorts. Although the correla-
tions between VO2peak and PCS were similar between the CKD and HTN patient cohort, at a
given VO2 peak the perceived physical score was significantly lower in the former group. To
our knowledge this is the first description of a clear link between a standardised objective mea-
sure of global biological function and HRQoL.
We found HRQoL measures to be significantly reduced for both PCS and MCS in our CKD
cohort, confirming previous observations [8–10] from similar CKD patient cohorts. Our
scores were somewhat higher than other dialysis cohorts[8, 10] probably due to our inclusion
of CKD patients fit enough to undergo a renal transplant. Hypertension is prevalent in CKD
and modulates cardiovascular function [14]. Therefore we selected patients with treated essen-
tial hypertension as a control group to the CKD population to investigate the potential role of
uremia itself on the interaction between subjective and objective functional measures in CKD.
Essential hypertension itself reduces quality of life measures [25] and impairs exercise toler-
ance [26] when compared to healthy individuals. Significantly reduced quality of life measures
Table 4. Univariate regression analysis of physical component score in the study cohorts.
Predictor CKD HTN
b 95% CI p-value b 95% CI p-value
Smoking -1.49 -3.55–0.57 0.2 -0.46 -1.89–0.98 0.5
BMI -0.17 -0.50–0.16 0.3 -0.16 -0.51–0.19 0.4
Diabetes -2.78 -7.66–2.11 0.3 - - -
Hypertension 0.21 -5.85–6.27 0.9 -0.86 -11.84–10.12 0.9
CV disease -0.26 -7.49–2.28 0.3
Dialysis vintage 0.00 -0.03–0.03 1.0 - - -
VO2peak 0.35 0.07–0.64 0.02 0.27 0.11–0.42 0.001
VO2AT 0.20 -0.48–0.87 0.6 0.47 0.17–0.76 0.002
HR at peak exercise 0.04 -0.02–0.10 0.2 0.07 0.01–0.13 0.03
Max work load 0.04 0.01–0.08 0.03 0.03 0.01–0.04 0.01
AIx75 -0.11 -0.22–0.01 0.07 0.03 -0.07–0.13 0.6
PWV 0.04 -0.55–0.63 0.9 -0.14 -0.75–0.47 0.7
MAP 0.03 -0.08–0.15 0.6 0.13 0.01–0.26 0.04
LV mass index 0.01 -0.04–0.05 0.7 0.06 -0.01–0.13 0.09
LV ejection fraction 0.01 -0.16–0.18 0.9 -0.08 -0.29–0.13 0.5
LA volume index 0.00 -0.11–0.11 1.0 -0.02 -0.18–0.14 0.8
E/mean e’ -0.13 -0.56–0.30 0.6 -0.09 -0.79–0.62 0.8
Hemoglobin 0.20 -0.85–1.25 0.7 -0.20 -1.19–0.79 0.7
Creatinine 0.00 -0.01–0.01 0.5 0.02 -0.06–0.11 0.6
Albumin 0.40 0.01–0.80 0.04 -0.10 -0.63–0.42 0.7
Calcium 2.59 -5.45–10.63 0.5 -3.91 -18.38–10.56 0.6
Phosphate -1.52 -5.20–2.15 0.4 0.77 -3.75–5.30 0.7
iPTH -0.01 -0.05–0.03 0.5 -0.38 -1.27–0.51 0.4
hs-CRP -0.01 -0.11–0.10 0.9 -0.21 -0.73–0.31 0.4
NT-proBNP 0.00 -0.01–0.01 0.6 0.05 -0.11–0.22 0.5
Troponin-T -0.01 -0.06–0.04 0.8 -0.03 -0.54–0.47 0.9
b, unstandardized regression coefficient: change in PCS per one unit change of variable.
https://doi.org/10.1371/journal.pone.0183926.t004
Quality of life measures predict cardiovascular health and physical performance in CKD
PLOS ONE | https://doi.org/10.1371/journal.pone.0183926 September 14, 2017 9 / 16
in CKD compared to HTN patients were reflected in much lower measures of cardiovascular
function in CKD patients as previously described[14, 27, 28].
Apart from serving indirectly as a marker for other prognostic factors, VO2peak directly
reflects the capacity to increase cardiac output, pulmonary function and skeletal muscle oxy-
gen utilisation in response to the physiologic stress of exercise. It is therefore plausible to
expect a correlation of VO2peak with patient experience of physical function in daily life as
demonstrated in our study. Reduced exercise tolerance is in part due to potentially reversible,
functional causes like physical deconditioning. It is encouraging that exercise programs are
able to improve exercise tolerance and in parallel quality of life, in particular physical function-
ing in patients with advanced CKD[15, 29, 30],[31, 32] and patients with essential hyperten-
sion [33] supporting a direct link between biological objective and perceived subjective
measurements. In fact physical inactivity likely contributes to increased morbidity and prema-
ture mortality for patients with CKD[33, 34].
The capacity to transport oxygen is determined by cardiovascular function and hemoglobin
concentration. Reduced cardiovascular capacity and hemoglobin concentration have been
shown to determine morbidity, mortality and HRQoL for patients with CKD[13, 14, 35–37].
For HTN patients HRQoL was improved when blood pressure was controlled [25]. We did
not find a correlation for echocardiographic or molecular measures of cardiac function, vascu-
lar elastance or hemoglobin concentration in the CKD or HTN cohort. Measures for cardio-
vascular function in a cross-sectional not preselected CKD population are usually found to be
lower[14, 38] compared to our CKD patients. However, LV ejection fraction does not correlate
with HRQoL measures even in patients with congestive heart failure [39]. High Troponin-T
but not NT-pro-BNP serum levels are associated with lower scores in physical function and
vitality domains from SF-36 in advanced CKD patients without symptomatic cardiac disease
or LV hypertrophy [40]. When using multiple regression analysis VO2peak remained a predic-
tive measure for PCS in both patient groups. CPET as the gold standard global exercise test is
Table 5. Multiple regression analysis of physical component score in CKD and HTN cohorts.
aModels b Standard Error 95% CI p–value
†Model I: CKD
Intercept 36.92 8.76 19.60–54.25 <0.001
Age 0.05 0.06 -0.08–0.17 0.5
Sex -0.69 1.68 -4.02–2.64 0.7
BMI -0.04 0.19 -0.42–0.34 0.8
Dialysis vintage 0.00 0.01 -0.02–0.03 0.8
VO2peak 0.39 0.18 0.03–0.74 0.03
†Model II: HTN
Intercept 57.82 9.55 38.82–76.82 <0.001
Age -0.18 0.08 -0.33 - -0.03 0.02
Sex 1.63 1.36 -1.07–4.33 0.2
BMI -0.10 0.17 -0.44–0.25 0.6
VO2peak 0.24 0.10 0.04–0.44 0.02
aAll models of CKD cohort adjusted for demographic variables age, sex, BMI and dialysis vintage; All models of HTN cohort adjusted for demographic
variables age, sex and BMI.
†Final model derived through variable selection process following initial inclusions of univariates with p<0.1. b, unstandardized regression coefficient:
change in PCS per one unit change of variable.
VO2peak, oxygen consumption at maximal exercise / kg body weight
https://doi.org/10.1371/journal.pone.0183926.t005
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likely measuring most aspects of physical HRQoL experience more accurately and is more sen-
sitive, a notion supported by the observation that all CPET measures correlate with PCS for
the HTN cohort.
The capacity for utilization of oxygen is related to skeletal muscle mass and function, which
are dependent on nutritional status. A measure for nutritional status is serum albumin. It pre-
dicts morbidity and mortality, but also quality of life, particularly of patients with CKD[9, 41].
Here we observed an association of albumin and PCS in CKD. On the contrary, we did not
observe a significant association between BMI and PCS among the CKD subjects despite the
recognition of higher BMI being paradoxically advantageous in advanced CKD[42, 43]. This
could be explained by the significantly lower BMI measured among the CKD subjects com-
pared to the HTN controls, suggesting the common policy of precluding patients from trans-
plant listing based on the BMI criterion. Major clinical risk factors such as diabetes,
hypertension or smoking also did not significantly predict the PCS but this could simply reflect
the limitation of using single surrogate marker as independent risk predictor[13, 44].
In both study cohorts, VO2peak was an independent predictor of PCS. However, it is inter-
esting to note that after adjusting the regression of PCS on VO2peak for demographic
Fig 2. A depicts the unadjusted regression of the PCS on VO2peak in the CKD and HTN cohorts. Unadjusted regression of Physical
Component Score on VO2peak in the CKD and HTN cohort. b, unstandardized regression coefficient: change in PCS per one unit
change of variable. *p–value<0.05. Dash line = HTN, straight line = CKD. B demonstrates the same regression after adjustment for
age, sex and BMI. Lack of difference of changes in VO2peak with Physical Component Score between the CKD and HTN cohorts. ΔB is
the difference in the parameter estimates between the regression lines for the HTN and CKD groups. Group interaction with VO2peak
was adjusted for age, sex, and BMI. Dash line = HTN, straight line = CKD.
https://doi.org/10.1371/journal.pone.0183926.g002
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characteristics gender, age and BMI there was no difference in the parameter estimates between
the regression lines. This suggests that PCS is a reliable composite predictor of CPET measures
and that the pathophysiological mechanism, treated hypertension with or without uremia did
not alter the correlation between functional measures and subjective experience. It is also
intriguing to note that for a given VO2peak the experienced PCS was much lower for patients
with CKD than for patients with HTN. Likely reasons are the systemic processes and effects
caused by CKD, uremia and also treatment modality resulted in reduced exercise tolerance
with associated reduced HRQoL. Blunted chronotropic and inotropic response to exercise [14],
cardiac stunning [21], decreased oxygen delivery [45], pulmonary congestion [46], anemia [47],
and skeletal muscle atrophy modulated by the upregulation of the IGF-1 signalling pathway
[48] have been described as potential mechanisms affecting CKD patients beyond hypertension.
Daily hemodialysis somewhat improves the perceived uremic effects [49] but more comprehen-
sive reversal of CKD effects are experienced by patients receiving a renal transplant [13].
Although the difference in VO2peak score between the two cohorts can explain a large part
of the discrepancy in HRQoL measured, other bio-psychosocial factors could also contribute
to the impaired HRQoL. Reduced exercise tolerance, other symptoms of uremia and frequent
hospital visits for dialysis can all contribute[1, 7]. As CKD progresses through from stage 1 to
5, all HRQoL dimensions have been shown to deteriorate. The largest deficits occur in PCS
and the smallest in mental health and bodily pain. Patients with CKD, on dialysis, have the
lowest scores across the stages in every domain [50]. Hemodialysis patients have lower QoL
scores compared with the general population in all dimensions[1, 50] but renal transplant
appears to reverse this deficit to scores near to general population norms[51].
In both CKD and HTN groups, the demographic, clinical and molecular variables tested
had no significant effect on the MCS[1, 5, 50]. This is in line with the literature in that clinical
variables have minimal effect on MCS in CKD[5, 50]. It is worth noting that MCS scores were
significantly lower in CKD than HTN. Mental well-being in patients with CKD can be affected
by multiple stressors. Fatigue, sleep disturbances, anorexia and cognitive dysfunction are asso-
ciated symptoms of uremia that can contribute to this [1]. For every ten point reduction in
MCS, there is an associated increase in mortality by 28%7.
Limitations
HRQoL is a subjective, very complex and dynamic process that is difficult to capture
completely in a single measure. Although we used the established HRQoL SF-36 questionnaire,
inclusion of CKD specific questions could have provided additional depth. Larger patient
cohorts are needed to break into each domain. Our findings are limited to patients with
advanced CKD and therefore further studies would need to assess if these findings can be sup-
ported across all stages of CKD.
Conclusion
For patients with CKD or HTN objective physical performance had a significant effect on self-
reported physical health and functioning. Self-reported physical health and functioning is a
reliable and useful tool to direct exercise programmes, transplant work-up and screen for risk.
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